CRP and cancer: A limited pattern of hallmarks of cancer could be clinically monitored, such as inflammation, via CRP response, in RCCC I/II (n = 18; n = 31) (Fig. 1), in MM (n = 6) and mLCH (n = 2), immune response in one patient with CRPC (CRPC I) (Fig. 2).